Drug intelligence / Profile preview

EP-303

Development stage: Preclinical
Lead developer: EndoPure Life Sciences
Modality: Small Molecules
Administration: Sublingual

Overview

EP-303 is a preclinical small molecule drug candidate being developed by EndoPure Life Sciences for the treatment of anxiety spectrum disorders. It utilizes a sublingual delivery system designed to optimize the bioavailability and therapeutic onset of cannabinoids. The drug's mechanism of action centers on modulating the crosstalk between the serotonergic and endocannabinoid systems, which are integral to the regulation of mood, stress, and anxiety. By targeting these interconnected pathways, EP-303 aims to provide a more effective and consistent clinical outcome compared to conventional oral cannabinoid administrations.

Targets

5-HT (Serotonin receptors)CB (Cannabinoid receptors)

Beyond the preview

Go deeper on EP-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-303.

Explore the full profile